首页 | 官方网站   微博 | 高级检索  
     

Endostatin? VEGF-C和VEGFR-3在非小细胞肺癌及其淋巴结组织中的表达与意义
引用本文:李少雷,陈晋峰,郑庆锋,吴楠,阎石,王洋,张建芝,杨跃.Endostatin? VEGF-C和VEGFR-3在非小细胞肺癌及其淋巴结组织中的表达与意义[J].中国肿瘤临床,2011,38(24):1519-1523.
作者姓名:李少雷  陈晋峰  郑庆锋  吴楠  阎石  王洋  张建芝  杨跃
作者单位:北京大学临床肿瘤学院胸外二科,北京肿瘤医院暨北京市肿瘤防治研究所,恶性肿瘤发病机制及转化研究教育部重点实验室 (北京市100142)
摘    要:探讨内皮抑素(endostatin)、血管内皮生长因子-C(VEGF-C)和血管内皮生长因子受体-3(VEGFR-3)在癌组织及其淋巴结组织中的表达与非小细胞肺癌(NSCLC)生物学行为之间的关系,了解endostatin、VEGF-C和VEGFR-3三者之间的内在联系。方法:使用免疫组化链霉菌抗生物素蛋白-过氧化物酶(SP)连接法对98例肺癌根治手术后癌组织和淋巴结组织标本的endostatin、VEGF-C和VEGFR-3的表达情况进行研究。结果:endostatin、VEGF-C、VEGFR-3在癌组织中的阳性表达率分别为30.6%、79.6%、61.2%。其中endostatin的表达与VEGF-C的表达呈正相关(P=0.025),VEGF-C的表达与VEGFR-3的表达呈正相关(P=0.007)。不同N分期及不同淋巴结转移枚数分组的患者,其endostatin和VEGF-C的阳性表达率均有显著性差异(P<0.05),且两者之间的变化呈相反趋势。VEGFR-3的表达与分化程度相关(P=0.013)。VEGF-C的表达情况与脉管癌栓相关(P=0.050)。在转移性淋巴结中,VEGF-C和VEGFR-3的阳性表达率均达88.0%,未转移淋巴结中,两者的阳性表达率分别为32.7%和57.1%,差异有统计学意义(P<0.001)。转移性淋巴结中微淋巴管密度(MLVD)明显高于非转移淋巴结(P<0.001)。结论:endostatin和VEGF-C的表达与肺癌淋巴结转移密切相关,endostatin可能通过下调VEGF-C的表达来抑制淋巴结转移,VEGF-C/VEGFR-3通路通过促进微淋巴管的增生直接参与淋巴结转移,对寻找治疗肺癌的新途径有重要意义。 

关 键 词:内皮抑素    血管内皮生长因子C    血管内皮生长因子受体3    非小细胞肺癌    淋巴结转移
收稿时间:2011-08-27

Expression and Clinical Evaluation of Endostatin,VEGF-C,and VEGFR-3 in Non-small Cell Lung Cancer and Lymph Node Tissues
Shaolei LI,Jinfeng CHEN,Qingfeng ZHENG,Nan WU,Shi YAN,Yang WANG,Jianzhi ZHANG,Yue YANG.Expression and Clinical Evaluation of Endostatin,VEGF-C,and VEGFR-3 in Non-small Cell Lung Cancer and Lymph Node Tissues[J].Chinese Journal of Clinical Oncology,2011,38(24):1519-1523.
Authors:Shaolei LI  Jinfeng CHEN  Qingfeng ZHENG  Nan WU  Shi YAN  Yang WANG  Jianzhi ZHANG  Yue YANG
Affiliation:Thoracic Surgery Ⅱ, Beijing Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing 100142, China
Abstract:To investigate the expression of endostatin, vascular endothelial growth factor C ( VEGF-C ), and vascular endothelial growth receptor 3 ( VEGFR-3 ) in non-small lung cancer ( NSCLC ) and lymph node tissues, and to explore their clinical significance. Methods: The immunohistochemical streptavidin-perosidase method was used to detect the expression of endostatin, VEGF-C, and VEGFR-3 in 98 cases of NSCLC after radical surgery. Results: The positive expression rates of endostatin, VEGF-C, and VEGFR-3 were 30.6%, 79.6%, and 61.2%, respectively. Endostatin and VEGF-C expression has significant correlation ( P = 0.025 ), whereas VEGF-C and VEGFR-3 expression also had significant correlation ( P = 0.007 ). Endostatin and VEGF-C expression in patients with different number of lymph node metastasis and N staging were significantly different ( P < 0.05 ). VEGFR-3 expression was correlated with differentiation ( P = 0.013 ), whereas VEGF-C expression was correlated with vascular thrombosis ( P = 0.050 ). The positive expression rates of endostatin and VEGF-C were 88% in positive lymph nodes, compared with the rates in negative lymph nodes which were 32.7% and 57.1% ( P < 0.001 ). More micro-lymphatic vessels were observed in the metastatic lymph nodes than in non-metastatic nodes. Conclusion: The expressions of endostatin and VEGF-C are related to lymphatic metastasis. Endostatin could decrease VEGF-C expression to inhibit lymphatic metastasis, and VEGF-C/VEGFR-3 could increase MLVD to help lymphatic metastasis, which is helpful for NSCLC therapy. 
Keywords:
本文献已被 万方数据 等数据库收录!
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号